<DOC>
	<DOC>NCT00904020</DOC>
	<brief_summary>Patients with a diagnosis of postherpetic neuralgia (PHN), diabetic neuropathy (DN), or low back pain (LBP) who were currently receiving an analgesic regimen that contained gabapentin participated in a Phase IV clinical trial to assess the effectiveness of Lidoderm® administered once daily (q24h) after 14 day in the treatment of PHN, DN, or LBP in patients who had a partial response to a regimen containing gabapentin.</brief_summary>
	<brief_title>A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Were currently receiving an analgesic regimen that contained gabapentin Had been on a stable dose of gabapentin for at least 14 days (same dose ±10% for 14 days) Had a partial response to a gabapentincontaining analgesic regimen defined as an average daily pain intensity score of &gt;4 on a ) to 10 scale, with 0 being no pain and 10 being pain as bas as the patients have ever imagined (Question 5 of the Brief Pain Inventory [BPI] within 24 hours prior to the screening visit For diabetic patients, had a hemoglobin A1c level &lt;0.13 (normal range, 0.0470.064) Had a neurological condition other than that associated with their pain diagnosis that, in the opinion of the investigator, would have interfered with their ability to participate in the study Had received an epidural steroid/local anesthetic injection within 14 days prior to study entry Had received trigger point injections within 14 days prior to study entry Had received Botox injections within 3 months prior to study entry Were taking a lidocainecontaining product that could not be discontinued while receiving Lidoderm Were taking Class 1 antiarrhythmic drugs (e.g., mexiletine, tocainide)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>